- Home
- SOGP vs TPST Comparison
SOGP vs TPST Comparison
Compare SOGP & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- TPST
- Stock Information
- Founded
- SOGP 2010
- TPST 2011
- Country
- SOGP Singapore
- TPST United States
- Employees
- SOGP N/A
- TPST N/A
- Industry
- SOGP
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- TPST Health Care
- Exchange
- SOGP NYSE
- TPST Nasdaq
- Market Cap
- SOGP 29.5M
- TPST 33.0M
- IPO Year
- SOGP 2020
- TPST N/A
- Fundamental
- Price
- SOGP $5.14
- TPST $7.76
- Analyst Decision
- SOGP
- TPST Hold
- Analyst Count
- SOGP 0
- TPST 3
- Target Price
- SOGP N/A
- TPST $30.00
- AVG Volume (30 Days)
- SOGP 151.4K
- TPST 80.4K
- Earning Date
- SOGP 08-05-2025
- TPST 08-07-2025
- Dividend Yield
- SOGP N/A
- TPST N/A
- EPS Growth
- SOGP N/A
- TPST N/A
- EPS
- SOGP N/A
- TPST N/A
- Revenue
- SOGP $278,363,908.00
- TPST N/A
- Revenue This Year
- SOGP $48.88
- TPST N/A
- Revenue Next Year
- SOGP N/A
- TPST N/A
- P/E Ratio
- SOGP N/A
- TPST N/A
- Revenue Growth
- SOGP N/A
- TPST N/A
- 52 Week Low
- SOGP $1.18
- TPST $5.35
- 52 Week High
- SOGP $6.89
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- SOGP 53.35
- TPST 63.65
- Support Level
- SOGP $5.03
- TPST $6.11
- Resistance Level
- SOGP $5.86
- TPST $6.49
- Average True Range (ATR)
- SOGP 0.85
- TPST 0.35
- MACD
- SOGP -0.19
- TPST 0.03
- Stochastic Oscillator
- SOGP 44.27
- TPST 100.00
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.